MBE Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Buy
887
+18
+2% +$18.4K 0.37% 40
2026
Q1
$799K Buy
869
+5
+0.6% +$5.07K 0.33% 41
2025
Q4
$928K Buy
864
+1
+0.1% +$956 0.39% 38
2025
Q3
$659K Buy
863
+16
+2% +$11.9K 0.28% 48
2025
Q2
$660K Buy
847
+23
+3% +$17.9K 0.29% 46
2025
Q1
$681K Buy
824
+220
+36% +$183K 0.33% 46
2024
Q4
$466K Sell
604
-53
-8% -$43.9K 0.26% 49
2024
Q3
$582K Buy
657
+56
+9% +$50.3K 0.32% 44
2024
Q2
$544K Sell
601
-1,003
-63% -$802K 0.33% 40
2024
Q1
$1.25M Buy
1,604
+153
+11% +$109K 0.77% 21
2023
Q4
$846K Buy
1,451
+1,030
+245% +$601K 0.43% 31
2023
Q3
$226K Buy
+421
New +$217K 0.13% 65
2020
Q2
Sell
-416
Closed -$57K 308
2020
Q1
$57K Buy
+416
New +$57.2K 0.05% 112

Other funds holding LLY

MBE Wealth Management's LLY Position: Q2 2026 in Review

MBE Wealth Management increased its Eli Lilly (LLY) stake by 2.1% in Q2 2026, buying an estimated $18.4K and bringing the position to 887 shares worth $1.06M. The position accounts for 0.37% of the portfolio, ranked #40.

MBE Wealth Management first reported a position in LLY in Q1 2020 and has held it in 13 quarters since. The position peaked at $1.25M in Q1 2024. 1,842 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • MBE Wealth Management held 887 shares of Eli Lilly worth $1.06M as of Q2 2026.
  • MBE Wealth Management bought 18 Eli Lilly shares in Q2 2026, an estimated $18.4K.
  • Eli Lilly made up 0.37% of MBE Wealth Management's portfolio in Q2 2026, its #40 holding.
  • MBE Wealth Management first reported a position in Eli Lilly in Q1 2020 and has held it in 13 quarters since.
  • MBE Wealth Management's Eli Lilly position peaked at $1.25M in Q1 2024.
  • 1,842 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on MBE Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.